

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00722
Patent 8,536,122

**PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, Patent Owner, Novo Nordisk A/S, hereby submits Mandatory Notice.

I. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1))

The real party-in-interest is Patent Owner Novo Nordisk A/S. Out of an abundance of caution, Patent Owner also identifies, as a potential real party-in-interest, exclusive licensee Novo Nordisk Inc. for purposes of providing notice. The listing of a potential real party-in-interest entity should not be deemed as an acknowledgement that, *inter alia*, any such entity actually controls this matter.

II. RELATED MATTERS (37 C.F.R. § 42.8(b)(2))

Novo Nordisk A/S identifies the following judicial and administrative matters that concern or concerned U.S. Patent No. 8,536,122.

- *Novo Nordisk Inc., et al. v. Viatris Inc.*, C.A. 23-13 (TSK) (N.D. W. Va.)
- *Novo Nordisk Inc., et al. v. Viatris Inc.*, C.A. 23-101 (CFC) (D. Del.)
- *Novo Nordisk Inc., et al. v. Mylan Pharmaceuticals Inc.*, C.A. 22-23 (IMK) (N.D. W. Va.) transferred to D. Del. as 22-1040 (CFC)
- *Novo Nordisk Inc. et al. v. Mylan Pharmaceuticals Inc.*, C.A. 22-1040 (CFC) (D. Del.)
- *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-3038 (CFC) (D. Del.)

- *Novo Nordisk Inc. et al. v. Rio Biopharmaceuticals, Inc. et al.*, C.A. 22-294 (CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Aurobindo Pharma USA, Inc. et al.*, C.A. 22-295 (CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Sun Pharmaceuticals Industries Ltd. et al.*, C.A. 22-296 (CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Zydus Worldwide DMCC et al.*, C.A. 22-297 (CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Dr. Reddy's Laboratories Ltd. et al.*, C.A. 22-298 (CFC) (D. Del.)
- *Novo Nordisk Inc. et al. v. Alvogen, Inc.*, C.A. 22-299 (CFC) (D. Del.)

The same petitioner has also challenged a related patent (No. 8,129,343) in IPR2023-00723.

**III. LEAD AND BACK-UP COUNSEL AND SERVICE
INFORMATION UNDER §§42.8(b)(3)-(4):**

Lead: J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5832
steve.baughman@groombridgewu.com

Backup: Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP

801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5878
megan.raymond@groombridgewu.com

Novo Nordisk A/S consents to service through the counsel identified above.

Electronic service of documents must be sent to each of the listed email addresses of the counsel *and* Novo-Semaglutide-IPR@groombridgewu.com. To the extent physical documents are served on Novo Nordisk A/S. please address any such correspondence to lead counsel and back-up counsel at the following mailing address: J. Steven Baughman, Megan Raymond, GROOMBRIDGE, WU, BAUGHMAN & STONE LLP, 801 17th Street, NW, Suite 1050, Washington, DC, 20006.

Respectfully submitted,

Dated: April 6, 2023

By: /s/ Megan Raymond

J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006
P: (202)-505-5832
steve.baughman@groombridgewu.com

Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC, 20006

P: (202)-505-5878
megan.raymond@groombridgewu.com

Attorneys for Patent Owner Novo Nordisk A/S

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of PATENT OWNER'S MANDATORY NOTICE UNDER 37 C.F.R. § 42.8 has been served in its entirety on April 6, 2023, by causing the aforementioned document to be electronically mailed to the following attorneys of record for the Petitioner listed below.

Petitioner's Counsel of Record:

Lead Counsel:	Brandon M. White Reg. No. 52,354 White-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 By Electronic Mail
Backup Counsel:	Emily J. Greb Reg. No. 68,244 Greb-ptab@perkinscoie.com Perkins Coie LLP 33 East Main Street Madison, WI 53703 Telephone: (608) 663-7460 Courtney Prochnow, PhD Reg. No. 67,639 Prochnow-ptab@perkinscoie.com Perkins Coie LLP 633 W. 5th St., Ste 5850 Los Angeles, CA 90071 Telephone: (310) 788-9900 Christopher D. Jones Reg. No. 76,472 Jones-ptab@perkinscoie.com

	Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 Jonathan I. Tietz, PhD Reg. No. 76,753 Tietz-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 Matthew A. Lembo Reg. No. 75,633 Lembo-ptab@perkinscoie.com Perkins Coie LLP 1155 Avenue of the Americas Floor 22 New York, NY 10036 Telephone: (212) 262-6900 Semaglutide-Ozempic@perkinscoie.com By Electronic Mail
--	--

Dated: April 6, 2023

Respectfully submitted,

By: /Sayem Osman
Sayem Osman